Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialAchim Rittmeyer, David R. Gandara, Fabrice Barlési et al.|The Lancet|2016Cited by 4.8k
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumabDavid R. Gandara, David S. Shames, Geoff Otto et al.|Nature Medicine|2018Cited by 1.2k
Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancerNamrata S. Patil, David S. Shames, Barzin Y. Nabet et al.|Cancer Cell|2022Cited by 403
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and ChemotherapyJoel W. Neal, Thomas Newsom-Davis, Dominic Curran et al.|Journal of Clinical Oncology|2024Cited by 57